# 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

> **NCT04018053** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 16 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** 18F-fluciclovine
- **DEVICE:** PET/CT

## Key facts

- **NCT ID:** NCT04018053
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-26
- **Primary completion:** 2024-06-30
- **Final completion:** 2026-07-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04018053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04018053, "18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04018053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*